menu

ReachMD

Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Conversations About PAH: Latest Developments and Key Insights for 2023 – Case Discussion

In this clinical discussion, you'll hear from two leading experts who will discuss patient cases and discuss how you can optimize PAH treatment plans based on risk stratification and comorbidities and integrate the evidence-based recommendations and treatments in your practice.

Live Broadcast
0.75 available credits
Information
June 15, 2023
06:00 PM - 06:45 PM EDT
ReachMD Healthcare Image

This live broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

Details
Presenters
Comments

  • Overview

    Pulmonary arterial hypertension (PAH) is a chronic and progressive condition that affects the pulmonary vasculature, resulting in elevated pulmonary vascular resistance, right ventricular dysfunction, and eventually, right heart failure. It is essential to identify and manage PAH early to improve patient outcomes. This necessitates comprehensive knowledge of the diagnostic criteria and classification of PAH, as well as a care approach based on evidence that incorporates the latest guidelines, advancements, and recommendations from leading professional organizations. In addition, due to the inadequacies of current therapies, it is necessary to critically evaluate novel treatment pathways and new/emerging therapeutic targets for PAH.

    In this clinical discussion, you'll hear from two leading experts who will discuss patient cases and discuss how you can optimize PAH treatment plans based on risk stratification and comorbidities and integrate the evidence-based recommendations and treatments in your practice.

  • Disclosure of Conflicts of Interest

    Disclosure
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

    Host
    Dr. Jennifer Caudle has no financial relationships to disclose.

    Faculty
    Dr. Richard N. Channick has disclosed the following relevant financial relationships:
    Consultant: Aria CV, Bayer, Enzyvant, Gossamer, Janssen,Third Pole, United Therapeutics

    Dr. Vallerie V. McLaughlin has disclosed the following relevant financial relationships:
    Consultant: Aerami, Aerovate, Altavant, Bayer, Caremark, L.L.C., Corvista, Gossamer Bio, Janssen, Merck, United Therapeutics
    Researcher: Aerovate, Altavant, Gossamer-Bio, Janssen, Merck, Sonovie

    AKH Staff and Planners
    Ruwaida Vakil, MSc, Medical Writer: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education and Operations: has no financial relationships to disclose.

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    The intended audience for this activity includes cardiologists, pulmonologists, nurse practitioners, physician assistants, nurses and other providers involved in the management of patients with pulmonary arterial hypertension (PAH). 

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Summarize the diagnostic criteria and classification of PAH to facilitate early identification and management.
    • Plan evidence-based care for patients with PAH informed by guideline recommendations, the latest developments, and key insights from leading professional organizations.
    • Critically review novel treatment pathways and new/emerging therapeutic targets for PAH.

  • Accreditation and Credit Designation Statements

     In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    0.75 ANCC contact hours

    Physician Assistants

    AAPA Credit Designation Statement 
    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

    Nurse Practitioners

    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.75 contact hour(s) (which includes 0.5 hour(s) of pharmacology).

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. 

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Criteria for Success
    To receive credit, participants should review the entire activity, complete and submit a posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at lritley@akhcme.com.

  • Provider(s)/Educational Partner(s)

    Credit provided by AKH Inc., Advancing Knowledge in Healthcare

  • Commercial Support

    Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Facebook Comments

Details
Presenters
Comments
Recommended

  • Overview

    Pulmonary arterial hypertension (PAH) is a chronic and progressive condition that affects the pulmonary vasculature, resulting in elevated pulmonary vascular resistance, right ventricular dysfunction, and eventually, right heart failure. It is essential to identify and manage PAH early to improve patient outcomes. This necessitates comprehensive knowledge of the diagnostic criteria and classification of PAH, as well as a care approach based on evidence that incorporates the latest guidelines, advancements, and recommendations from leading professional organizations. In addition, due to the inadequacies of current therapies, it is necessary to critically evaluate novel treatment pathways and new/emerging therapeutic targets for PAH.

    In this clinical discussion, you'll hear from two leading experts who will discuss patient cases and discuss how you can optimize PAH treatment plans based on risk stratification and comorbidities and integrate the evidence-based recommendations and treatments in your practice.

  • Disclosure of Conflicts of Interest

    Disclosure
    It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

    Host
    Dr. Jennifer Caudle has no financial relationships to disclose.

    Faculty
    Dr. Richard N. Channick has disclosed the following relevant financial relationships:
    Consultant: Aria CV, Bayer, Enzyvant, Gossamer, Janssen,Third Pole, United Therapeutics

    Dr. Vallerie V. McLaughlin has disclosed the following relevant financial relationships:
    Consultant: Aerami, Aerovate, Altavant, Bayer, Caremark, L.L.C., Corvista, Gossamer Bio, Janssen, Merck, United Therapeutics
    Researcher: Aerovate, Altavant, Gossamer-Bio, Janssen, Merck, Sonovie

    AKH Staff and Planners
    Ruwaida Vakil, MSc, Medical Writer: has no financial relationships to disclose.
    Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
    Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
    Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education and Operations: has no financial relationships to disclose.

    All of the relevant financial relationships listed for these individuals have been mitigated.

  • Target Audience

    The intended audience for this activity includes cardiologists, pulmonologists, nurse practitioners, physician assistants, nurses and other providers involved in the management of patients with pulmonary arterial hypertension (PAH). 

  • Learning Objectives

    Upon completion of the educational activity, participants should be able to:

    • Summarize the diagnostic criteria and classification of PAH to facilitate early identification and management.
    • Plan evidence-based care for patients with PAH informed by guideline recommendations, the latest developments, and key insights from leading professional organizations.
    • Critically review novel treatment pathways and new/emerging therapeutic targets for PAH.

  • Accreditation and Credit Designation Statements

     In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    0.75 ANCC contact hours

    Physician Assistants

    AAPA Credit Designation Statement 
    AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. 

    Nurse Practitioners

    AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.75 contact hour(s) (which includes 0.5 hour(s) of pharmacology).

    Disclaimer
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content. 

    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Criteria for Success
    To receive credit, participants should review the entire activity, complete and submit a posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at lritley@akhcme.com.

  • Provider(s)/Educational Partner(s)

    Credit provided by AKH Inc., Advancing Knowledge in Healthcare

  • Commercial Support

    Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Presenters

Facebook Comments

Recommended

Schedule2 Jun 2023
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended